144 related articles for article (PubMed ID: 31624331)
1. Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review.
Eektimmerman F; Swen JJ; Madhar MB; Allaart CF; Guchelaar HJ
Pharmacogenomics J; 2020 Apr; 20(2):159-168. PubMed ID: 31624331
[TBL] [Abstract][Full Text] [Related]
2. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.
Kung TN; Dennis J; Ma Y; Xie G; Bykerk V; Pope J; Thorne C; Keystone E; Siminovitch KA; Gagnon F
Arthritis Rheumatol; 2014 May; 66(5):1111-20. PubMed ID: 24782176
[TBL] [Abstract][Full Text] [Related]
3. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
4. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
[TBL] [Abstract][Full Text] [Related]
5. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
[TBL] [Abstract][Full Text] [Related]
6. Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.
Hakamata J; Kaneko Y; Shimizu M; Yamaoka K; Maruyama J; Takeuchi T; Mochizuki M; Hashiguchi M
Biol Pharm Bull; 2018; 41(9):1414-1422. PubMed ID: 30175777
[TBL] [Abstract][Full Text] [Related]
7. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
Wessels JA; van der Kooij SM; le Cessie S; Kievit W; Barerra P; Allaart CF; Huizinga TW; Guchelaar HJ;
Arthritis Rheum; 2007 Jun; 56(6):1765-75. PubMed ID: 17530705
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.
Bohanec Grabar P; Leandro-García LJ; Inglada-Pérez L; Logar D; Rodríguez-Antona C; Dolžan V
Pharmacogenomics; 2012 Nov; 13(14):1583-94. PubMed ID: 23148635
[TBL] [Abstract][Full Text] [Related]
9. [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 2)].
Swierkot J; Slęzak R
Postepy Hig Med Dosw (Online); 2011 Mar; 65():207-15. PubMed ID: 21502697
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Qiu Q; Huang J; Shu X; Fan H; Zhou Y; Xiao C
Sci Rep; 2017 Mar; 7():44015. PubMed ID: 28266606
[TBL] [Abstract][Full Text] [Related]
11. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC
Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
[TBL] [Abstract][Full Text] [Related]
12. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M
Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981
[TBL] [Abstract][Full Text] [Related]
13. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
[TBL] [Abstract][Full Text] [Related]
14. [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1)].
Swierkot J; Slęzak R
Postepy Hig Med Dosw (Online); 2011 Mar; 65():195-206. PubMed ID: 21502696
[TBL] [Abstract][Full Text] [Related]
15. Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line.
Imamura H; Yoshina S; Ikari K; Miyazawa K; Momohara S; Mitani S
Mod Rheumatol; 2016 Jul; 26(4):507-16. PubMed ID: 26587663
[TBL] [Abstract][Full Text] [Related]
16. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
17. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
Nomair AM; Abdelati A; Dwedar FI; Elnemr R; Kamel YN; Nomeir HM
Clin Rheumatol; 2024 Mar; 43(3):971-983. PubMed ID: 38311638
[TBL] [Abstract][Full Text] [Related]
18. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Sousa H; Azevedo R; Costa L; Ventura F; Seabra V; Medeiros R
Pharmacogenomics; 2014 Apr; 15(6):807-20. PubMed ID: 24350725
[TBL] [Abstract][Full Text] [Related]
19. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
[TBL] [Abstract][Full Text] [Related]
20. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Świerkot J; Ślęzak R; Karpiński P; Pawłowska J; Noga L; Szechiński J; Wiland P
Pol Arch Med Wewn; 2015; 125(3):152-61. PubMed ID: 25599563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
